The result of adjuvant chemotherapy for localized pT3 upper urinary tract carcinoma in a multi-institutional study
- 257 Downloads
To determine through the analysis of our multi-institutional database whether postoperative adjuvant chemotherapy for upper urinary tract carcinoma with localized invasive upper urinary tract carcinoma (UUTC) is beneficial.
A study population of 93 patients with pT3N0/xM0 UUTC was eligible for this study. Clinical features evaluated were sex, tumor location, adjuvant chemotherapy status, tumor pathology (histology, grade, infiltrating growth, lymphovascular invasion (LVI)), and cause of death. Cancer-specific survival (CSS) was estimated by Kaplan–Meier method. Prognostic factors related to CSS were analyzed by Cox proportional hazards regression model for multivariate analysis.
In pT3 patients, overall 5-year CSS rate was 68.4% and median CSS time was 31 months (range 3–114 months). In the adjuvant chemotherapy group, 5-year CSS rate was 80.8%, whereas 5-year CSS rate was 64.4% in the non-adjuvant chemotherapy group. By multivariate analysis, adjuvant chemotherapy status was significantly associated with CSS (P = 0.008) were sex, tumor grade, tumor histology, and LVI presence.
This study, although it was retrospective study, revealed that adjuvant chemotherapy after RNU may be beneficial in pT3N0/X patients by multivariate analysis. Prospective studies evaluating adjuvant therapy regimens for UTTC are required.
KeywordsUpper urinary tract Urothelial carcinoma Adjuvant chemotherapy Retrospective study Prognostic factor
Upper urinary tract
Magnetic resonance imaging
Carcinoma of upper urinary tract
The American Joint Committee on Cancer
Union Internationale Contre le Cancer
Estimated glomerular filtration rate
Methotrexate, vinblastine, doxorubicin, and cisplatin
Gemcitabine and cisplatin
Methotrexate, epirubicin, and cisplatin
Methotrexate, epirubicin, and nedaplatin
The authors wish to thank the investigators, their staff, and the affiliated institutions for the important contribution to this study in The Osaka Urinary Tract Urothelial Carcinoma Collaboration Group: Kensaku Nishimura, Susumu Miyoshi, (Osaka Rosai Hospital); Ken Takeda, (Osaka Medical Center for Cancer and Cardiovascular Diseases); Seiji Yamaguchi, (Osaka General Medical Center Hospital); Yoichi Shiotsuka, Shigeru Nakamori, (Higashiosaka City General Hospital); Toshiaki Yoshioka, (Sumitomo Hospital); Satoko Fukuda, Tsuneo Hara, (Ikeda Municipal Hospital); Hideki Sugao, (Minoh City Hospital); Mototaka Sato, Koji Hatano, Masatoshi Mukai, Akira Nagahara, Motohide Uemura, Daizo Oka, (Osaka University).
Conflict of interest
There are no sources of support to declare, and no author has any financial disclosures or conflicts of interest to declare.
- 6.Greene FL, Page DL, Fleming ID et al (2002) American Joint Committee on Cancer (AJCC) staging manual, 6th edn. Springer, PhiladelphiaGoogle Scholar
- 7.Mostofi FK, Sobin LH, Torioni H (1973) Histological typing of urinary bladder tumors. World Health Organization, GenevaGoogle Scholar